Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

Last updated: June 18, 2019
Sponsor: University of Saskatchewan
Overall Status: Active - Recruiting

Phase

4

Condition

Angina

Myocardial Ischemia

Chest Pain

Treatment

N/A

Clinical Study ID

NCT03980990
OA-UofS-778
  • Ages > 18
  • All Genders

Study Summary

This pilot randomized controlled trial aims to evaluate the feasibility for safety examination of continued metformin therapy in patients with type 2 diabetes (T2D) following invasive coronary angiography. Metformin will be continued until coronary angiography.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years

  2. On metformin therapy

  3. Angiography for ACS or elective non-ACS related indications

  4. Informed consent received

Exclusion

Exclusion Criteria:

  1. Cardiogenic shock prior to randomization

  2. Cardiac arrest prior to randomization

  3. Established severe CKD (eGFR<30, or on dialysis)

  4. Chronic liver disease

  5. Need for CABG within 48 hours of hospitalization

  6. Inability to follow the protocol and comply with follow-up requirements or any otherreason that the investigator feels would place the patient at increased risk if theinvestigational therapy is initiated

Study Design

Total Participants: 500
Study Start date:
June 17, 2019
Estimated Completion Date:
June 17, 2020

Connect with a study center

  • Royal University Hospital

    Saskatoon, Saskatchewan S7N0W8
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.